title: Global assessment of antimicrobial susceptibility among Gram-negative organisms collected from pediatric patients between 2004 and 2012: results from the Tigecycline Evaluation and Surveillance Trial.
abstract: The Tigecycline Evaluation and Surveillance Trial (TEST) was designed to monitor susceptibility to commonly used antimicrobial agents among important pathogens. We report here on susceptibility among Gram-negative pathogens collected globally from pediatric patients between 2004 and 2012. Antimicrobial susceptibility was determined using guidelines published by the Clinical and Laboratory Standards Institute (CLSI). Most Enterobacteriaceae showed high rates of susceptibility (>95%) to amikacin, tigecycline, and the carbapenems (imipenem and meropenem); 90.8% of Acinetobacter baumannii isolates were susceptible to minocycline, and susceptibility rates were highest in North America, Europe, and Asia/Pacific Rim. Amikacin was the most active agent against Pseudomonas aeruginosa (90.4% susceptibility), with susceptibility rates being highest in North America. Extended-spectrum β-lactamases (ESBLs) were reported for 11.0% of Escherichia coli isolates and 24.2% of Klebsiella pneumoniae isolates globally, with rates reaching as high as 25.7% in the Middle East and >43% in Africa and Latin America, respectively. Statistically significant (P<0.01) differences in susceptibility rates were noted between pediatric age groups (1 to 5 years, 6 to 12 years, or 13 to 17 years of age), globally and in some regions, for all pathogens except Haemophilus influenzae. Significant (P<0.01) differences were reported for all pathogens globally and in most regions, considerably more frequently, when pediatric and adult susceptibility results were compared. Amikacin, tigecycline, and the carbapenems were active in vitro against most Gram-negative pathogens collected from pediatric patients; A. baumannii and P. aeruginosa were susceptible to fewer antimicrobial agents. Susceptibility rates among isolates from pediatric patients were frequently different from those among isolates collected from adults.
authors: Medical College of Wisconsin, Milwaukee, Wisconsin, USA kskehl@mcw.edu.
authors: Sue C
authors: SC
authors: Kehl
authors: Pfizer Inc., Collegeville, Pennsylvania, USA.
authors: Michael J
authors: MJ
authors: Dowzicky
mesh_terms: D000293:Adolescent; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D002648:Child; D002675:Child, Preschool; D024881:Drug Resistance, Bacterial; D062665:Epidemiological Monitoring; D005260:Female; D014943:Global Health; D006090:Gram-Negative Bacteria / Q000187:drug effects* / Q000302:isolation & purification; D016905:Gram-Negative Bacterial Infections / Q000453:epidemiology / Q000382:microbiology*; D006801:Humans; D007223:Infant; D008297:Male; D008826:Microbial Sensitivity Tests; D008911:Minocycline / Q000031:analogs & derivatives* / Q000494:pharmacology; D062211:Spatio-Temporal Analysis; D000078304:Tigecycline
chemical_list: D000900:Anti-Bacterial Agents; D000078304:Tigecycline; D008911:Minocycline
references: Clin Ther. 2012 Feb;34(2):496-507.e1
references: 22249106
references: Infez Med. 2012 Sep;20(3):176-81
references: 22992557
references: BMJ Case Rep. 2011;2011. pii: bcr0220113807. doi: 10.1136/bcr.02.2011.3807
references: 22688471
references: Rev Chilena Infectol. 2012 Jun;29(3):317-21
references: 23096472
references: Infez Med. 2012 Dec;20(4):296-8
references: 23299072
references: Int J Antimicrob Agents. 2013 Mar;41(3):224-8
references: 23305657
references: Surg Infect (Larchmt). 2013 Apr;14(2):203-8
references: 23540793
references: J Antimicrob Chemother. 2013 Jul;68 Suppl 2:ii45-55
references: 23772046
references: Pak J Biol Sci. 2008 Feb 1;11(3):422-7
references: 18817166
references: J Antimicrob Chemother. 2009 Apr;63(4):775-80
references: 19158109
references: Pediatr Infect Dis J. 2013 Jun;32(6):636-40
references: 23838732
references: J Clin Microbiol. 2009 May;47(5):1613
references: 19403778
references: J Med Microbiol. 2010 Feb;59(Pt 2):213-9
references: 19833780
references: Eur J Clin Microbiol Infect Dis. 2010 Mar;29(3):301-5
references: 20063025
references: J Med Assoc Thai. 2009 Dec;92 Suppl 7:S164-72
references: 20232569
references: Pediatr Infect Dis J. 2010 Apr;29(4):310-3
references: 20216475
references: Int Urol Nephrol. 2009 Dec;41(4):953-7
references: 18704743
references: Am J Infect Control. 2010 May;38(4):308-14
references: 20123152
references: Chemotherapy. 2010;56(6):492-500
references: 21099222
references: Int Urol Nephrol. 2011 Jun;43(2):549-55
references: 20524067
references: Eur J Clin Microbiol Infect Dis. 2011 Sep;30(9):1095-103
references: 21347680
references: J Antimicrob Chemother. 2011 Nov;66(11):2677-8
references: 21846669
references: Jpn J Infect Dis. 2012 Jul;65(4):318-21
references: 22814155
references: Antimicrob Agents Chemother. 2012 Sep;56(9):4765-70
references: 22733062
references: Rev Soc Bras Med Trop. 2012 Jul-Aug;45(4):475-9
references: 22767099
references: Pediatrics. 2012 Sep;130(3):e615-22
references: 22891227
references: Pediatr Crit Care Med. 2012 Sep;13(5):501-8
references: 22460772
references: Turk J Pediatr. 2012 Jan-Feb;54(1):59-60
references: 22397044